gms | German Medical Science

58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

26. bis 29.04.2007, Leipzig

Expression of lymphangiogenesis-related factors in malignant gliomas

Expression lymphangiogener Faktoren in malignen Gliomen

Meeting Abstract

  • corresponding author S. Grau - Neurochirurgische Klinik, Klinikum Großhadern, Ludwig-Maximilian Universität München
  • F. Trillsch - Neurochirurgische Klinik, Klinikum Großhadern, Ludwig-Maximilian Universität München
  • I. v. Lüttichau - Medizinische Klinik und Poliklinik, Klinikum Innenstadt, Ludwig-Maximilian Universität München
  • P. Nelson - Medizinische Klinik und Poliklinik, Klinikum Innenstadt, Ludwig-Maximilian Universität München
  • J.-C. Tonn - Neurochirurgische Klinik, Klinikum Großhadern, Ludwig-Maximilian Universität München
  • R. Goldbrunner - Neurochirurgische Klinik, Klinikum Großhadern, Ludwig-Maximilian Universität München

Deutsche Gesellschaft für Neurochirurgie. 58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC). Leipzig, 26.-29.04.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. DocP 093

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2007/07dgnc348.shtml

Veröffentlicht: 11. April 2007

© 2007 Grau et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Tumour induced angiogenesis is a key feature of malignant gliomas representing a novel target for neoadjuvant therapies. Glioma vessels are characterized by irregular shape, glomerulum-like formations and widespread thrombosis. Besides receptors and mechansims well known from hemangiogenesis we investigated the presence and origin of several lymphatic markers such as VEGFR3, VEGF-C, VEGF-D, podoplanin, prox-1 and LYVE-1.

Methods: Expression of VEGFR3, VEGF-C and –D, podoplanin, Prox-1, and Lyve-1 was investigated in human gliomas of different grade (n: GBM=18, WHO°III=10, WHO°II=6) and non neoplastic brain (n=3) on protein level by immunohistochemistry and Western Blotting, mRNA level was measured by real-time PCR. Epitope carrying cells were isolated from tumor tissue and further characterized by FACS and immunofluorescence.

Results: Lymphatic markers VEGFR3, podoplanin and Prox-1 are strongly expressed in all malignant gliomas investigated (WHO°III and IV). VEGFR3 was almost entirely located on tumor endothelium, while podoplanin was localised in perivascular tissue in WHO° IV tumors but expressed also on tumor endothelium in WHO°III. Low grade tumors WHO°II showed little to no expression. Non neoplastic brain was negative for all antigens investigated. VEGFR3+ cells showed expression of typical endothelial markers, while podoplanin+ cells showed a complex antigen pattern including CD14 and CD146.

Conclusions: Lymphatic factors are highly expressed in malignant gliomas (WHO°III and IV) while being absent in low grade tumors. This links to a grade dependent expression of these factors promising new insights into the angiogenic switch during glioma progression.